The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 195,842 | 7,393,059 | SH | DFND | 7,393,059 | 0 | 0 | ||
ELEVEN BIOTHERAPEUTICS INC | COM | 286221106 | 13,653 | 4,841,591 | SH | DFND | 4,841,591 | 0 | 0 | ||
SAGE THERAPEUTICS INC | COM | 78667J108 | 640,434 | 8,773,073 | SH | DFND | 8,773,073 | 0 | 0 | ||
ZAFGEN INC | COM | 98885E103 | 110,887 | 3,202,045 | SH | DFND | 3,202,045 | 0 | 0 |